

Financial news for OSIR dated on 2019-03-12: Osiris Therapeutics Shares Resume Trade

Financial news for OSIR dated on 2019-03-12: Osiris Therapeutics, Inc. Shares To Resume Trade At 9:50 a.m. EDT

Financial news for OSIR dated on 2019-03-12: Osiris Shares Halted Ahead Of Announcement Of Acquisition By Smith & Nephew

Financial news for OSIR dated on 2019-03-12: Osiris Therapeutics To Be Acquired By Smith & Nephew For \$19/Share In Cash, Or approximately \$660.5M Total

Financial news for OSIR dated on 2019-03-12: The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Financial news for OSIR dated on 2019-03-06: The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

Financial news for OSIR dated on 2019-02-21: The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

Financial news for OSIR dated on 2019-02-06: The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Financial news for OSIR dated on 2019-02-05: The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Financial news for OSIR dated on 2018-12-12: Stocks Which Set New 52-Week High Yesterday, Tues., Dec. 11, 2018

Financial news for OSIR dated on 2018-12-12: The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

Financial news for OSIR dated on 2018-12-10: Stocks Which Set New 52-Week High The Last Trading Session, Fri., Dec. 7, 2018

Financial news for OSIR dated on 2018-11-26: Osiris Therapeutics, Inc. Appoints Samson Tom To Serve As President And Chief Executive Officer

Financial news for OSIR dated on 2018-11-07: Osiris Therapeutics Q3 EPS \$0.12 Down From 0.22 YoY, Sales \$36.49M Up From \$29.81M Est.

Financial news for OSIR dated on 2018-10-30: Osiris Therapeutics, Inc. To Present Advanced Clinical And Scientific Abstracts At Symposium On Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, In Las Vegas, Nevada

Financial news for OSIR dated on 2018-09-18: The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Financial news for OSIR dated on 2018-08-28: The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetrphase's Antibiotic

Financial news for OSIR dated on 2018-08-16: The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Financial news for OSIR dated on 2018-08-15: The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

Financial news for OSIR dated on 2018-08-14: The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Financial news for OSIR dated on 2018-08-10: The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss

Financial news for OSIR dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for OSIR dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for OSIR dated on 2018-08-01: Osiris Therapeutics Reports Will Re List On Nasdaq Wed., Aug. 1, 2018

Financial news for OSIR dated on 2017-03-28: 20 Biggest Mid-Day Gainers For Tuesday

Financial news for OSIR dated on 2017-03-13: 12 Biggest Mid-Day Losers For Monday

Financial news for OSIR dated on 2017-03-13: Mid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares Plunge

Financial news for OSIR dated on 2017-03-13: Mid-Morning Market Update: Markets Mostly Lower; Intel To Buy Mobileye For \$15 Billion

Financial news for OSIR dated on 2017-03-13: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for OSIR dated on 2017-01-27: Mid-Afternoon Market Update: Celestica Rises On Earnings Beat; KEYW Shares Slide

Financial news for OSIR dated on 2016-12-28: Aetna Spokesperson Confirms Osiris' Grafix Added To Wound Care Medically Necessarily List On 12/23/16

Financial news for OSIR dated on 2016-12-28: Osiris Shares Volatile Here, Make Parabolic Move Over Last Few Mins as Traders Passing Around Aetna Site on Wound Care Mentioning Osiris Grafix

Financial news for OSIR dated on 2016-12-02: Osiris Receives Letter From NASDAQ Granting Extension Of Listing Provided Company Becomes Current With SEC Filings By March 10, 2017

Financial news for OSIR dated on 2016-11-22: Osiris Announces Publication Of Positive Study Outcomes For Its Grafix Treatment In Peer-Reviewed Publication

Financial news for OSIR dated on 2016-11-21: Osiris Therapeutics Offers Update on NASDAQ Listing Matters: Co. Requested Added Time to File Delinquent Reports at Nov. 10, 2016 Hearing; Co. Continues to Work Diligently to Close Previously Announced Accounting Reviews

Financial news for OSIR dated on 2016-11-08: Mid-Afternoon Market Update: BioScrip Drops Following Q3 Results; Earthstone Energy Shares Spike Higher

Financial news for OSIR dated on 2016-11-08: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for OSIR dated on 2016-11-08: Mid-Day Market Update: U.S. Stocks Turn Positive; Hertz Shares Drop Following Downbeat Earnings

Financial news for OSIR dated on 2016-11-08: Mid-Morning Market Update: Markets Open Lower; CVS Health Issues Weak Guidance

Financial news for OSIR dated on 2016-11-08: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OSIR dated on 2016-11-07: Osiris Therapeutics Estimates That 2014 Will Restate Rev. To \$46-\$50M, 2015 Rev. \$85-\$90M; Sees FY16 Rev. \$100-\$110M vs. Est. \$110M

Financial news for OSIR dated on 2016-10-06: Osiris Therapeutics Appoints Alberto Avendano Chief Medical Officer

Financial news for OSIR dated on 2016-08-17: Osiris Provides Update Regarding NASDAQ Listing Matters

Financial news for OSIR dated on 2016-08-04: Osiris Therapeutics Product Grafix Reporting Positive Outcomes In Exposed Tendon and Bone Clinical Trial

Financial news for OSIR dated on 2016-05-17: MiMedx Files Lawsuit Against Osiris, Citing False And Misleading Representations

Financial news for OSIR dated on 2016-05-11: Osiris Therapeutics Files Non-Timely 10Q

Financial news for OSIR dated on 2016-05-02: Osiris Therapeutic's Grafix Shows Greater Clinical Outcomes Compared With EpiFax In "Real-World Study"

Financial news for OSIR dated on 2016-04-14: Osiris Terminated its Chief Medical Officer, Jon Hopper -8K

Financial news for OSIR dated on 2016-04-08: Osiris Reports Further Expansion of Grafix Commercial Coverage: Health Plan Lives Grew by 9.5M During Mar.

Financial news for OSIR dated on 2016-03-24: MoxReports @MoxReports Tweet: Osiris Therapeutics Beset By Newer And Bigger Troubles
<http://moxreports.com/2016/03/24/osiris-therapeutics-beset-by-newer-and-bigger-troubles/> ...

Financial news for OSIR dated on 2016-03-16: Osiris Therapeutics Offers Update on Clinical Review by Blue Cross Blue Shield: Sufficient Evidence to Determine Technology Results in Meaningful Improvement in Net Health Outcome

Financial news for OSIR dated on 2016-03-16: Mid-Afternoon Market Update: Dow Gains

125 Points; Crude Oil Up 5%

Financial news for OSIR dated on 2016-03-16: Shares of Osiris Therapeutics Resume Trade Following Circuit Breaker; Down ~7.8%

Financial news for OSIR dated on 2016-03-16: Stocks Hitting 52-Week Lows

Financial news for OSIR dated on 2016-03-15: Stocks Hitting 52-Week Lows

Financial news for OSIR dated on 2016-03-09: Mid-Afternoon Market Update: Crude Oil Rises 3.5%; Zagg Shares Fall Following Weak Q4 Results

Financial news for OSIR dated on 2016-03-03: Osiris Names Dwayne Montgomery CEO

Financial news for OSIR dated on 2016-02-04: Mid-Day Market Update: GoPro Slides Following Earnings Miss; Carpenter Technology Shares Surge

Financial news for OSIR dated on 2016-02-04: Mid-Morning Market Update: Markets Drop; ConocoPhillips Posts Wider Loss

Financial news for OSIR dated on 2016-02-03: Osiris Therapeutics Names Dwayne Montgomery Interim CFO, Frank Czworka COO; Replaces Dr. Lode Debrabandere Who Resigned Due To Personal Reasons

Financial news for OSIR dated on 2016-01-19: Osiris Responds to Internet Posts Regarding The Company

Financial news for OSIR dated on 2016-01-15: Negative Mox Report Out on Osiris

Financial news for OSIR dated on 2016-01-05: Osiris Therapeutics' Stock Is Higher On Tuesday: Here's Why

Financial news for OSIR dated on 2016-01-05: Mid-Morning Market Update: Markets Edge Higher; Commercial Metals Posts Lower Q1 Earnings

Financial news for OSIR dated on 2016-01-05: Osiris Issues Update on Coverage for Grafix: Gets Confirmed Medicare Coverage from Cahaba, Effective Jan. 1; Signs Contract with Major GPO

Financial news for OSIR dated on 2015-12-18: Brean Says Osiris Therapeutics Likely To See Selling Pressure Today, Anticipates Further Accounting Issues In 10K Audit

Financial news for OSIR dated on 2015-11-17: Mid-Afternoon Market Update: Dicks Sporting Goods Slips On Earnings Miss; Airgas Shares Spike Higher

Financial news for OSIR dated on 2015-11-17: Mid-Day Market Update: Dow Rises 100 Points; Urban Outfitters Shares Slide On Weak Sales

Financial news for OSIR dated on 2015-11-17: Stocks Hitting 52-Week Lows

Financial news for OSIR dated on 2015-11-17: Mid-Morning Market Update: Markets Edge Higher; Wal-Mart Profit Beats Expectations

Financial news for OSIR dated on 2015-11-17: Morning Market Losers

Financial news for OSIR dated on 2015-11-17: Benzinga's Top Downgrades

Financial news for OSIR dated on 2015-11-17: Brean Digs Into Osiris Therapeutics 10Q, Downgrades To Sell

Financial news for OSIR dated on 2015-11-17: Brean Capital Downgrades Osiris Therapeutics to Sell, Announces \$8.00 PT

Financial news for OSIR dated on 2015-11-06: Osiris Therapeutics Reports Q3 EPS \$(0.02), Sales \$24.286M vs \$25M Est.

Financial news for OSIR dated on 2015-10-30: Brean's Jason Wittes on Osiris Therapeutics: 'Oversold, Especially Since It Already Started BLA Process for Grafix'

Financial news for OSIR dated on 2015-10-06: Osiris Reports Initiation of Phase III Trial for OTI-15-01 for Treatment of Chronic Diabetic Foot Wounds

Financial news for OSIR dated on 2015-10-01: Why Brean's Jason Wittes Is Watching Osir Therapeutics

Financial news for OSIR dated on 2015-10-01: Brean Capital Assumes Osiris Therapeutics at Hold

Financial news for OSIR dated on 2015-09-21: Osiris Therapeutics Names Gregory Law as

CFO

Financial news for OSIR dated on 2015-09-17: Osiris Announces \$0.20/Share Special Dividend; Names Gregory Law as CFO, Dwayne Montgomery as Chief Business Officer

Financial news for OSIR dated on 2015-08-05: Osiris Therapeutics Reports Q2 Product Sales \$23.7M vs \$23.6M Est., EPS \$0.03 vs \$0.06 Est.

Financial news for OSIR dated on 2015-05-21: Osiris Evaluates the Establishment Of An International Subsidiary

Financial news for OSIR dated on 2015-05-08: Osiris Therapeutics Reports Q1 EPS \$0.04 Vs Est \$0.00, Sales \$21M Vs Est \$18.40M

Financial news for OSIR dated on 2015-04-09: Osiris Therapeutics Names Dr. Alla Danilkovitch Chief Scientific Officer

Financial news for OSIR dated on 2015-03-05: Osiris Therapeutics Reports Q4 EPS from Cont. Ops. \$0.03 vs \$0.05 Est., Sales \$19.3M vs \$18.9M Est.

Financial news for OSIR dated on 2015-02-09: Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest Profit Margin

Financial news for OSIR dated on 2014-12-31: Benzinga's Volume Movers

Financial news for OSIR dated on 2014-12-29: Brean Capital Initiates Coverage On Osiris Therapeutics

Financial news for OSIR dated on 2014-12-29: Brean Capital Initiates Coverage on Osiris Therapeutics at Buy, Announces \$19.00 PT

Financial news for OSIR dated on 2014-12-22: Osiris Announces a Strategic Partnership with Stryker for Marketing Osiris' Viable Bone Matrix

Financial news for OSIR dated on 2014-12-03: Osiris Therapeutics Appoints Adrian Mollo As General Counsel, Jon Hopper As Chief Medical Officer

Financial news for OSIR dated on 2014-11-07: Osiris Therapeutics, Inc. Reports Q3 Revenue of \$17.20M vs \$14.76M Est

Financial news for OSIR dated on 2014-10-17: Osiris, Arthrex Announce Exclusive Deal for Commercialization, Development of Cartiform

Financial news for OSIR dated on 2014-09-16: RF Lafferty & Co. Initiates Coverage on Osiris Therapeutics, Inc. at Buy, Announces \$19.00 PT

Financial news for OSIR dated on 2014-08-07: Osiris Therapeutics, Inc. Reports Q2 EPS of \$(0.05), Up 55% YOY; Revenue of \$13.30M vs \$11.0M Est

Financial news for OSIR dated on 2014-07-10: Osiris Therapeutics Shares Spike Lower; May be Attributed to Seeking Alpha Pro Post

Financial news for OSIR dated on 2014-03-17: Osiris Therapeutics Files Form to Delay 10K

Financial news for OSIR dated on 2014-03-05: Osiris Therapeutics, Inc. Reports Q4 EPS of \$0.11

Financial news for OSIR dated on 2014-03-05: Earnings Scheduled For March 5, 2014

Financial news for OSIR dated on 2013-12-18: Journal Publishes Grafix Clinical Study for Chronic Wounds

Financial news for OSIR dated on 2013-12-02: Osiris Therapeutics Announces Mills Stepping Down as Pres, CEO, Says Debrabandere to Assume Roles

Financial news for OSIR dated on 2013-12-02: Osiris Therapeutics CEO Mills Stepping Down for Personal Reasons

Financial news for OSIR dated on 2013-11-29: Osiris Therapeutics Reports CMS Decides to Package Reimbursement for Products Used in Advanced Wound Care with the Related Surgical Procedure into Two-Tier System

Financial news for OSIR dated on 2013-11-19: Osiris Therapeutics Says Trial on Grafix Met All Primary, Secondary Endpoints

Financial news for OSIR dated on 2013-11-01: Osiris Therapeutics, Inc. Reports Q3 EPS of \$(0.05) vs \$(0.10) Est; Revenue of \$6.88M vs \$6.70M Est

Financial news for OSIR dated on 2013-10-21: Market Wrap for Monday, October 21: Dow Closes Down, S&P and Nasdaq Close Up

Financial news for OSIR dated on 2013-10-21: Mid-Afternoon Market Update: JC Penney Falls on Massive Volume Following Imperial Capital Price Target

Financial news for OSIR dated on 2013-10-21: Osiris Legal Team Responds, Says Reviewing All of Legal-Regulatory Options, Calls TheStreet Story 'Misleading'

Financial news for OSIR dated on 2013-10-21: FDA Releases Ovation, Grafix PRIME, Grafix CORE, Grafix XC Untitled Letter

Financial news for OSIR dated on 2013-10-21: Mid-Day Market Update: Hasbro Surges On Upbeat Earnings; Gannett Shares Tumble

Financial news for OSIR dated on 2013-10-21: Mid-Morning Market Update: Markets Mixed; McDonald's Posts Higher Q3 Profit

Financial news for OSIR dated on 2013-10-21: UPDATE: Osiris Shares Fall 14% on 8-K Announcing Agreement with FDA on Regulatory Pathway for Grafix and Ovation

Financial news for OSIR dated on 2013-10-21: Osiris, FDA Have Announced Pact on Regulatory Pathway for Biosurgery

Financial news for OSIR dated on 2013-10-11: Osiris Therapeutics Off the Highs Following the Sale of its Stem Cell Business; Shares Currently Up Over 14.4%

Financial news for OSIR dated on 2013-10-10: Mesoblast Acquires Culture Expanded Stem Cell Therapeutic Business from Osiris

Financial news for OSIR dated on 2013-10-02: Market Wrap For October 2: Dollar Moves As Shutdown Continues

Financial news for OSIR dated on 2013-10-02: Mid-Afternoon Market Update: Tesla Drops on Baird Downgrade and YouTube Video

Financial news for OSIR dated on 2013-10-02: UPDATE: Piper Jaffray Upgrades Osiris Therapeutics, Pull-Back Offers Attractive Entry Point

Financial news for OSIR dated on 2013-10-02: Piper Jaffray Upgrades Osiris Therapeutics, Inc. to Overweight, Maintains \$21.00 PT

Financial news for OSIR dated on 2013-08-14: Benzinga's Top Pre-Market Gainers

Financial news for OSIR dated on 2013-08-13: Mid-Afternoon Market Update: Apple Rises Sharply On Icahn Stake, NASDAQ Pulled Upward

Financial news for OSIR dated on 2013-08-13: UPDATE: Piper Jaffray Downgrades Osiris Therapeutics on DFU Data

Financial news for OSIR dated on 2013-08-13: Mid-Day Market Update: US Stocks Edge Higher; Valspar Shares Decline On Downbeat Results

Financial news for OSIR dated on 2013-08-13: Piper Jaffray Downgrades Osiris Therapeutics, Inc. to Neutral

Financial news for OSIR dated on 2013-08-13: Mid-Morning Market Update: Markets Drop, Yum China Same-Store Sales Down 13%

Financial news for OSIR dated on 2013-08-13: Benzinga's Volume Movers

Financial news for OSIR dated on 2013-08-13: Stocks Hitting 52-Week Highs

Financial news for OSIR dated on 2013-08-13: Morning Market Movers

Financial news for OSIR dated on 2013-08-13: Osiris Reports Strong Efficacy for Grafix to Treat Diabetic Foot Ulcers

Financial news for OSIR dated on 2013-08-12: Osiris Therapeutics to Hold Call on Grafix Trial Aug. 13th at 9AM EDT

Financial news for OSIR dated on 2013-08-05: Osiris Therapeutics, Inc. Reports Q2 EPS of \$(0.11) vs \$(0.09) Est

Financial news for OSIR dated on 2013-08-05: Earnings Scheduled For August 5, 2013

Financial news for OSIR dated on 2013-05-07: Osiris Therapeutics, Inc. Reports Q1 EPS of \$(0.08) vs \$(0.09) Est

Financial news for OSIR dated on 2013-03-06: Market Wrap for Wednesday, March 6: Stocks Close Mixed as Euro Tests Key Support Level Ahead of ECB Meeting

Financial news for OSIR dated on 2013-03-06: UPDATE: Piper Jaffray Upgrades Osiris Therapeutics to Overweight on Strong Biosurgery Growth

Financial news for OSIR dated on 2013-03-06: Piper Jaffray Upgrades Osiris Therapeutics, Inc. to Overweight, Maintains \$11.50 PT

Financial news for OSIR dated on 2013-03-06: Osiris Therapeutics, Inc. Reports Q4 EPS of \$(0.08) vs \$(0.15) Est

Financial news for OSIR dated on 2013-03-06: Earnings Scheduled For March 6, 2013

Financial news for OSIR dated on 2013-02-19: Osiris Therapeutics Wins Title of European Orphan Drug Status for Prochymal

Financial news for OSIR dated on 2013-02-18: Osiris Therapeutics Concludes Successful Defense of Stem Cell Patent Challenge in Australia

Financial news for OSIR dated on 2012-09-28: Swissmedic Says Osiris Prochymal Therapeutics Prochymal to be Evaluated Under Rapid Authorization Procedure

Financial news for OSIR dated on 2012-09-28: Osiris Therapeutics Regains Worldwide Rights to Prochymal and Chondrogen

Financial news for OSIR dated on 2012-09-20: Osiris Therapeutics Says Board Member Barnhill Passed Away; Elects Klingemann in Place

Financial news for OSIR dated on 2012-08-07: Osiris Therapeutics Spikes Higher

Financial news for OSIR dated on 2012-07-30: Osiris Therapeutics Reports Q2 EPS \$-0.13 vs \$-0.15 Est; Revenues \$1.63M vs \$1.57M Est

Financial news for OSIR dated on 2012-07-13: Osiris Selected by BARDA to Submit Proposal for the Use of Grafix(r) in Mass Casualty Thermal Burn Injuries

Financial news for OSIR dated on 2012-07-05: These Are Four of the Hottest Biotechs in the Market Right Now

Financial news for OSIR dated on 2012-07-02: Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart Attack

Financial news for OSIR dated on 2012-06-20: 'Biological Legos' Could Become a Blockbuster Innovation For Osiris Therapeutics

Financial news for OSIR dated on 2012-06-18: Osiris Therapeutics Trading 19.4% Higher on Heavy Volume; Currently at \$10.96

Financial news for OSIR dated on 2012-06-15: Bullish setups to watch next week

Financial news for OSIR dated on 2012-06-14: Osiris Receives Second Approval for Life-Saving Stem Cell Drug; Prochymal Granted Marketing Consent by New Zealand

Financial news for OSIR dated on 2012-05-30: Benzinga's Top Pre-Market Gainers

Financial news for OSIR dated on 2012-05-29: Osiris Receives Medicare Reimbursement Codes for Grafix

Financial news for OSIR dated on 2012-05-18: Benzinga's Top Pre-Market Gainers

Financial news for OSIR dated on 2012-05-11: Earnings Scheduled For May 11

Financial news for OSIR dated on 2012-03-09: Piper Jaffray Maintains Osiris Therapeutics at Neutral, Lowers PT from \$7 to \$5

Financial news for OSIR dated on 2012-03-09: Earnings Scheduled For March 9

Financial news for OSIR dated on 2012-02-10: From Earlier: Osiris Therapeutics Provides Update Regarding the Genzyme/Sanofi Relationship

Financial news for OSIR dated on 2012-01-03: Osiris Therapeutics Provides Update on Groundbreaking Stem Cell Trial for Type 1 Diabetes

Financial news for OSIR dated on 2012-01-03: Osiris Therapeutics Provides Update on Groundbreaking Stem Cell Trial for Type 1 Diabetes

Financial news for OSIR dated on 2011-07-27: US Judge Dismisses Stem-Cell Funding

Challenge

Financial news for OSIR dated on 2011-04-29: Court Ruling For Embryonic Stem Cells Boost Stocks (STEM, CELG, OSIR)

Financial news for OSIR dated on 2011-03-15: Benzinga's Top Pre-Market NASDAQ Gainers (OSIR, APWR, JASO, FSLR)

Financial news for OSIR dated on 2011-03-07: Osiris Therapeutics Reports Q4 EPS of \$0.13

Financial news for OSIR dated on 2011-03-07: Osiris Therapeutics Reports Q4 EPS of \$0.13 vs. \$0.09

Financial news for OSIR dated on 2011-03-07: Earnings Scheduled For March 7 (KCAP, URBN, KRO, HMIN, CASY, OSIR, FLL, IPCM, CIEN, OUTD, SHEN, PWRD)

Financial news for OSIR dated on 2011-01-14: Health Canada Requests Additional Information for Approval of Prochymal

Financial news for OSIR dated on 2010-12-09: Osiris Therapeutics (OSIR) - Bull of the Day

Financial news for OSIR dated on 2010-12-09: Osiris Therapeutics (OSIR) - Bull of the Day

Financial news for OSIR dated on 2010-11-12: Osiris EPS Up on Lower Costs - Analyst Blog

Financial news for OSIR dated on 2010-11-11: Zacks Releases Four Powerful 'Buy' Stocks: Osiris Therapeutics, Bancolombia, JAKKS Pacific and ReneSola Limited - Press Releases

Financial news for OSIR dated on 2010-11-11: Osiris Therapeutics - Aggressive Growth

Financial news for OSIR dated on 2010-11-05: Osiris Therapeutics Reports Third Quarter EPS of \$.14

Financial news for OSIR dated on 2010-08-09: Osiris Beats on Cost Control - Analyst Blog

Financial news for OSIR dated on 2010-07-21: Prochymal New Drug Submission Granted Priority Review by Health Canada (OSIR)

Financial news for OSIR dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?